No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.

Leusink M1, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH.

Author information

Abstract

AIM:

Genetic variation has been shown to influence statin response in terms of lowering LDL cholesterol. The recently discovered CYP3A4*22 allele (defined as rs35599367) has been shown to affect statin-induced LDL cholesterol lowering. Our objective was to investigate whether this polymorphism modifies the risk reduction for myocardial infarction (MI) by statins.

PATIENTS & METHODS:

We analyzed the interaction between the *22 minor allele and statin use in the independent Utrecht Cardiovascular Pharmacogenetics study and Rotterdam Study, using logistic and Cox regression models.

RESULTS:

In total, 771 MI cases and 6131 controls were included in the analyses. There was no effect of the CYP3A4*22 allelic status in the studies separately, nor when the estimates from both studies were combined (interaction odds ratio: 1.27; 95% CI: 0.73-2.21; p = 0.40 for carriers of the minor T-allele).